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ABSTRACT
Objective To analyse paediatric exposures to pod and
traditional laundry detergents in Italy and changes in
exposure trends.
Methods Analyses of a series of patients aged
<5 years and exposed to laundry detergents between
September 2010 and June 2015, identified by the
National Poison Control in Milan.
Results In comparison with patients exposed to
traditional laundry detergents (n=1150), a higher
proportion of those exposed to pods (n=1649) were
managed in hospital (68% vs 42%), had clinical effects
(75% vs 22%) and moderate/high severity outcomes
(13% vs <1%). Exposure rates were stable over time for
traditional detergents (average 0.65 cases/day), but an
abrupt decline in major company pods was seen in
December 2012, 4 months after the introduction of
opaque outer packaging (from 1.03 to 0.36 cases/day
and from 1.88 to 0.86 cases/million units sold). The
odds of clinical effects was higher for exposure to pods
than for traditional detergents (OR=10.8; 95% CI 9.0 to
12.9). Among patients exposed to pods, the odds of
moderate/high severity outcomes was four times higher
for children aged <1 years than for the other age groups
(OR=3.9; 95% CI 2.2 to 7.0). Ten children exposed to
laundry detergent pods had high severity outcomes
while no children exposed to traditional laundry
detergents developed high severity effects.
Conclusions The study confirms that exposure to
laundry detergent pods is more dangerous than exposure
to traditional detergents. In Italy, 4 months after the
introduction of opaque outer packaging by a major
company, product-specific exposure rates decreased
sharply, suggesting that reducing visibility of laundry
detergent pods may be an effective preventive measure.
Further efforts are needed to improve safety.
INTRODUCTION
Liquid laundry detergent pods (LDPs) are unit dose
fabric washing products consisting of about 32–
50 mL of concentrated liquid detergent wrapped in
a water-soluble membrane. According to the
International Association for Soaps, Detergents and
Maintenance Products (AISE), these products are
intended to improve environmental sustainability of
liquid laundry detergent consumption by providing
the correct dosage for washing needs and reducing
packaging size.1 However, following their launch in
the UK, Irish, and French markets in 2001, a few
reports of paediatric poisonings and injuries high-
lighted the potential for these products to cause eye
damage,2–7 pulmonary and central nervous system
toxicity5–10 and serious laryngopharyngeal injur-
ies.6 11 A decade later, these products were
introduced into other national markets without
considering the need for specific measures to
prevent exposures. Consequently, these countries
started to document cases of patients with LDP
exposures presenting with severe respiratory,
oesophageal, gastric,12–18 eye19–21 and skin injur-
ies,22–24 together with cases of altered mental
status.12 13 Studies based on large series of cases
handled by Poison Control Centres (PCCs) or
emergency departments confirmed that LDP-related
cases are more likely to develop signs/symptoms
and moderate/high severity clinical effects than
those exposed to traditional laundry detergents
(TLDs).20 25–31
LDPs were initially launched in the Italian
market in mid-August 2010; they were sold in see-
through outer packaging by a major company
(MC) and 1 year later in the same way by other
companies (OCs). In the days after the MC-LDPs
launch, the National Poison Control Centre in
Milan (NPCCMi) started receiving an increasing
number of requests for toxicological assistance of
young children exposed to laundry detergents and
with unexpected respiratory and ocular effects. It
became immediately evident that the observed
events were associated with the new product.22
Therefore, NPCCMi contacted the company manu-
facturing the product associated with the reported
cases, AISE and the Ministry of Health to make the
case for taking preventive measures. This alert
initiated the monthly monitoring of exposures to
laundry detergents by NPCCMi and the Italian
National Institute of Health.
After considering the information provided
about cases of exposure to LDPs, a series of volun-
tary initiatives were undertaken by the MC and
OCs: in January 2011, the precautionary statement
“keep out of reach of children”, together with the
corresponding icon, was introduced during
MC-LDP television advertisements. Furthermore,
the icon was made more prominent on the see-
through outer packaging. In January 2012, an add-
itional opening/closing latch was added to the lid
of the outer packaging of MC-LDPs to make it
more difficult for young children to open. Between
May and June 2012, the MC and OCs launched an
educational campaign in major newspapers and
magazines to promote safe use and storage of
LDPs. Finally, since August 2012, MC-LDPs have
begun to be marketed in opaque outer packaging.
Subsequently, the Ministry decree of 18 December
2012,32 made the measures proposed by AISE man-
datory.1 From January 2013, the LDPs see-through
outer packaging had to be labelled with the precau-
tionary statements “keep away from children” and
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“close the lid/bag properly” together with the corresponding
standard icons or it had to be sold with a pamphlet reporting
the same precautionary statement and corresponding icon. From
June 2013, the outer packaging of the newly commercialised
products needed to be opaque with a closure impeding the
ability of young children to open the packaging —that is, requir-
ing a coordinated action of both hands and more strength to
open it, together with a yellow label reporting the above indi-
cated precautionary statements and corresponding icons. Of
note, in January 2014, LDPs still available in see-through outer
containers had to be withdrawn from the market.
Our study aimed to compare the main characteristics of
paediatric exposures to LDPs and TLDs that occurred in Italy
between September 2010 and June 2015 and to analyse changes
in exposure rates and trends after the introduction of preventive
measures during the study period.
METHODS
Data sources
Each year, NPCCMi receives approximately 42 000 reports of
human exposure to different types of agents, accounting for
more than 60% of all cases referred to the Italian PCCs. Most
requests for toxicological assistance handled by NPCCMi are
made by hospitals (60% of cases) and the general public (30%
of cases) throughout Italy. Assistance with diagnosis and treat-
ment of poisonings is provided by medical toxicologists, usually
over the phone. For each case handled, the consulting toxicolo-
gist uses a standard form to collect the following categories of
data: demographics, exposure characteristics (eg, substance/com-
mercial product, route of exposure, circumstances, dose and
latency between exposure and onset of clinical effects), signs
and symptoms, treatment and outcome. Data on the quantity of
MC-pods and OCs-pods sold were provided by the MC,
expressed as million units sold/month between February 2010
and December 2014.
Case selection criteria
For this study, all cases of unintentional exposure to laundry
detergents between 1 September 2010 and 30 June 2015 were
extracted from the NPCCMi database. These cases were
searched using NPCCMi hierarchical code of products, which
qualifies the exposure of interest as non-pharmaceutical (first
level), household cleaning product (second level) and laundry
detergent (third level).33 The subsequent associated code levels
are intended to provide the following pieces of information:
type of detergent and physical form (fourth level) —that is,
TLD, liquid/solid; LDP, liquid/half liquid and half solid, product
brand name and company (fifth level). Unintentional exposure
to laundry detergents was found in 3470 cases, of which 2958
(85%) were in children aged <5 years and were included in the
study. Patients aged ≥5 years were excluded from the study.
Among the included cases, 1150 patients were exposed to TLDs
(39%) and 1649 were exposed to LDPs (56%). One hundred
fifty-nine cases (5%) were excluded from the study because it
was unknown if the laundry detergent was a TLD or a LDP.
Among patients exposed to LDPs, 1188 (72%) were exposed to
MC-LDPs and 461 (28%) to OCs-LDPs.
Variables
The variables analysed included: site of case management (hos-
pital/non-hospital), demographic characteristics (age and
gender; month and year of exposure), route of exposure, clinical
effects and treatments. The product companies were classified
into two groups—MC, covering 100% to 50% of the Italian
market during the study period, and OCs. Data collected for
each symptomatic case were reviewed by one of the authors
(FD), a clinical toxicologist, to evaluate the association between
clinical effects and exposure. Additionally, severity of outcome
was graded according to the Poisoning Severity Score,34—that
is, none—no signs/symptoms; low—mild, transient and spontan-
eously resolving signs/symptoms, including eye irritation/
redness, rash, skin redness/irritation, oral cavity irritation/
redness, emesis (one to three episodes), diarrhoea (one to three
episodes), self-resolving cough, sore tongue/mouth/throat; mod-
erate—pronounced or prolonged signs/symptoms, including
corneal ulceration, skin erythema/burns, emesis (more than
three episodes), diarrhoea (more than three episodes), persistent
cough, difficulty in breathing not requiring intubation, burning
sensation of the mouth, transient drowsiness/central nervous
system depression; high—life-threatening signs/symptoms or
resulting in significant residual disability or disfigurement,
including oedema of epiglottis/glottis/pharynx/larynx, difficulty
in breathing requiring intubation, persistent drowsiness/ central
nervous system depression, corrosive injuries of the gastrointes-
tinal tract, metabolic acidosis, melena; fatal—death as a result
of exposure or of direct complications of the exposure effects;
not associated—no signs/symptoms possibly related to the
exposure; insufficient data—the available information is indica-
tive of a causal relationship between exposure and an adverse
health effect but it is inadequate for severity grading.
Statistical methods and ethical considerations
The characteristics of patients exposed to the two main categor-
ies of laundry detergents were compared by Pearson’s χ2 test or
Fisher’s exact test. The following occurrence measures were cal-
culated: mean number of cases of exposure/day by month, year
and category of laundry detergent, mean number of cases of
exposure to LDPs/million units sold by month, year and
company —that is, MC vs OCs. Information on the quantity
sold between September 2010 and December 2015 was pro-
vided by the MC. To determine whether an occurrence change
had taken place during the study period, the series of rates esti-
mates were analysed according to the procedure described by
Taylor for performing a change-point analysis.35 This procedure
iteratively uses a combination of cumulative sum charts
(CUSUM) and bootstrapping analysis, which provides for each
detected point a confidence level indicating how confident the
analysis is that the change actually occurred, and a CI indicating
how well the time of change point has been pinpointed.
Changes at 95% or higher confidence level of rates calculated as
number of patients exposed to LDPs/millions units sold by
month and company were used to define pre- and post-change
periods for subsequent analyses. The mean numbers of cases of
exposure to LDPs/month observed in the pre- and post-change
periods, adjusted by quantity sold, were compared using analysis
of variance. Regression analysis was subsequently used to quan-
tify the exposure period effect according to the change in the
mean number of cases/month, along with its 95% CIs.
Further statistical analyses were carried out to check the sensi-
tivity to different distributional assumptions—that is, Poisson
regression, using the quantity sold as an offset. To account for
variance heterogeneity, regression models were also used on
transformed data. In particular, the square root transformation
was used to stabilise the variance. Two logistic regression
models were used to measure the effect of exposure to laundry
detergents as a risk factor for clinical effects (none; at least one)
and their severity (none/low severity; moderate/high severity),
by maximum likelihood estimate of the ORs and the related
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95% CIs, adjusted by age (<1 year; 1–2 years; 3–4 years) and
exposure period (pre-change-point period; post-change-point
period).
The analyses were performed using STATA statistic package
V.11 and Taylor change-point analyzer (StataCorp, Stata
Statistical Software: release 12. College Station, TX: StataCorp
LP, 2011; Taylor W Change-Point Analyzer 2.0 shareware
program. Libertyville, Illinois: Taylor Enterprises).
This study was approved by the ethical committee of
Niguarda Hospital.
RESULTS
General characteristics and management site
The main characteristics of patients exposed to TLDs and LDPs
are described in table 1.
The two groups exposed to either TLDs or LDPs showed dif-
ferent distribution by gender age, and route of exposure
(p<0.001, respectively). In comparison with patients exposed
to TLDs, patients exposed to LDPs included a higher propor-
tion of female subjects (48% vs 41%), tended to be older, with
a higher proportion of children aged 3 years (18% vs 12%) or 4
years (10% vs 5%), and were more often exposed via multiple
routes (12% vs 6%), mainly ingestion in combination with eye
and/or skin (8% vs 3%). Children exposed to LDPs were more
often managed at hospital (68% vs 42%, p<0.001).
Clinical effects and treatments
As shown in table 2, patients exposed to LDPs more often had
clinical effects (75% vs 22%, p<0.001), and developed moder-
ate/high severity effects (13% vs <1% (based on one case of
moderate severity), p<0.0001). No deaths associated with
laundry detergent exposure were seen. Among symptomatic
cases, those exposed to LDPs more often developed gastrointes-
tinal (76% vs 66%, p<0.01) oropharyngeal (27% vs 12%,
p<0.001) and respiratory (19% vs 11%, p<0.01) effects than
those exposed to TLDs. A number of signs were observed only
among patients exposed to LDPs, including lips/oral cavity
oedema and de-epithelisation (7 cases, respectively), laryngos-
pasm/bronchospasm (19 cases), lung sounds such as wet rales
(14 cases) and stridor (7 cases), bronchial hypersecretion (11
cases), respiratory failure (6 cases), glottis/oesophagus caustic
injuries/erosion (5 cases), glottis/epiglottis oedema (3 cases),
chemical pneumonia (3 cases), corneal abrasion (22 cases) and
rash (8 cases).
In both groups the vast majority of patients received at least
one treatment (LDPs: 99%; TLDs, 94%), and, more specifically,
at least a symptomatic treatment (LDPs: 92%; TLDs: 84%)
(table 3). Patients exposed to LDPs were more frequently
treated with H2 blockers (32% vs 6%, p<0.001), steroids (4%
vs 1%, p<0.001), antibiotics (3% vs 0.3%, p<0.001) and fluids
intravenous (2% vs 0.6%, p<0.01).
In both groups, antidotal therapy referred only to dimethi-
cone/simethicone administration, with a significantly higher per-
centage of patients treated among those exposed to LDPs (62%
vs 51%, p<0.001).
None of the patients exposed to TLDs was given supportive
care, while seven patients exposed to LDPs required support
ventilation and one patient was intubated.
Rate changes and trends
The monthly mean number of patients/day exposed to TLDs
compared with the two LDPs groups—that is, MC-LDPs and
OCs-LDPs, is shown in figure 1A, B. A change is indicated by an
interruption of the background colour. No change-points were
identified for the mean number of patients/day exposed to
TLDs (overall estimated average: 0.65 cases/day) (figure 1A, B).
The mean number of patients/day exposed to MC-LDPs under-
went a change in December 2012 (CI December 2012 to
December 2012) at a confidence level of 100% (figure 1A).
Before the observed change the estimated average was 1.03
cases/day, while it became 0.36 cases/day in the post-change
period. Three consecutive changes were observed for the mean
number of patients/day exposed to OCs-LDPs (figure 1B). They
included an upward change detected in April 2012 (CI April
2012 to April 2012) at a confidence level of 100%, with esti-
mated averages increasing from 0.24 cases/day (August 2011 to
March 2012) to 0.53 cases/day (April to November 2012), and
two subsequent rate decreases. The first one, identified in
December 2012 (CI December 2012 to June 2013; confidence
level: 98%), indicated that between December 2012 and
September 2013 the estimated average was reduced from 0.53
to 0.38 cases/day; the second one, identified in October 2013
(CI April 2013 to March 2014; confidence level: 98%), indi-
cated that between October 2013 and June 2015 the observed
average was further reduced from 0.38 to 0.25 cases/day.
The change-point analysis based on the number of patients
exposed to LDPs/million units sold by month and company is
shown in figure 1C. The observed results confirmed an abrupt
change of MC-LDP exposure rates in December 2012 (CI
Table 1 Characteristics of children aged <5 years and exposed to
laundry detergents in Italy between September 2010 and June 2015
Characteristics LDPs TLDs Total
n %† n %† n %†
Gender***
Female 791 48.0 470 40.9 1261 45.1
Male 856 51.9 680 59.1 1536 54.9
Unknown 2 0.1 0 0.0 2 0.1
Age (years)***
<1 95 5.8 52 4.5 147 5.3
1 621 37.7 489 42.5 1110 39.7
2 484 29.4 415 36.1 899 32.1
3 289 17.5 135 11.7 424 15.1
4 160 9.7 59 5.1 219 7.8
Route of exposure***
Single route 1452 88.1 1072 93.2 2524 90.2
Ingestion 1363 82.7 1025 89.1 2388 85.3
Eye 76 4.6 28 2.4 104 3.7
Skin 13 0.8 19 1.7 32 1.1
Multiple routes 197 11.9 73 6.3 270 9.6
Ingestion and eye 84 5.1 17 1.5 101 3.6
Ingestion eye and skin 27 1.6 8 0.7 35 1.3
Ingestion and skin 28 1.7 9 0.8 37 1.3
Eye and skin 54 3.3 36 3.1 90 3.2
Other 4 0.2 3 0.3 7 0.3
Unknown 0 0.0 5 0.4 5 0.2
Management site***
Hospital 1123 68.1 477 41.5 1600 57.2
Private residence 526 31.9 673 58.5 1199 42.8
***p<0.001.
†The column percentages were calculated using the total number of patients exposed
to LDPs (n=1649), TLDs (n=1150) and total (n=2799), respectively.
LDP, laundry detergent pod; TLD, traditional laundry detergent.
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October 2012 to December 2012; confidence level: 100%). In
the pre-change-point period the estimated average was 1.88
cases/million units sold, while in the post-change-point period
(December 2012 to December 2014) it was reduced to 0.86
cases/million units sold. No change was detected for OCs-LDP
exposure rates (overall estimated average: 0.95 cases/million
units sold).
Analysis of variance performed taking into account the quan-
tity of LDPs sold, confirmed that in the post-change-point
period—that is, between December 2012 and December 2014,
there was a statistically significant reduction in the mean
number of patients exposed to MC-LDPs, accounting for −19.6
cases/month (95% CI −23.2 to −16.1, p<0.0001). The sensitiv-
ity analysis supported the normal based inference (Poisson
period coefficient=−0.77, p<0.001). However, when using the
transformed data to take into account the data heterogeneity of
variance, the statistical significance of the period effect was
reduced (Poisson period coefficient=−0.26, p=0.054).
Risk analyses of clinical effects and their severity
The logistic regression analysis carried out on all patients
exposed to laundry detergents (table 4, model 1) showed that
the odds of having at least one clinical effect, adjusted by expos-
ure period and age, was similarly increased among patients
exposed to MC-LDPs (OR=10.5; 95% CI 8.6 to 12.8) and
Table 3 Treatments reported for children aged <5 years and
exposed to laundry detergents in Italy between September 2010
and June 2015
LDPs TLDs Total
Treatments n %† n %† n %†
At least one treatment***
No 18 1.1 74 6.4 92 3.3
Yes 1631 98.9 1076 93.6 2707 96.7
Symptomatic treatment*** 1522 92.3 962 83.7 2484 88.7
Antacids/mucosal protection 1396 84.7 942 81.9 2338 83.5
H2 blockers*** 521 31.6 69 6.0 590 21.1
Steroids*** 66 4.0 13 1.1 79 2.8
Antibiotics*** 49 3.0 4 0.3 53 1.9
Fluids intravenous** 37 2.2 7 0.6 44 1.6
Other** 44 2.7 12 1.0 56 2.0
Antidote 1029 62.4 587 51.0 1616 57.7
Dimethicone/simethicone*** 1029 62.4 587 51.0 1616 57.7
Decontamination/absorption
prevention***
295 17.9 103 9.0 398 14.2
Dilute/irrigate/wash—ocular*** 162 9.8 56 4.9 218 7.8
Emesis/ipecac*** 109 6.6 20 1.7 129 4.6
Dilute/irrigate/wash—dermal 62 3.8 37 3.2 99 3.5
Activated charcoal 4 0.2 1 0.1 5 0.2
Supportive care 7 0.4 0 0.0 7 0.3
Artificial ventilation 6 0.4 0 0.0 6 0.2
Intubation 1 0.1 0 0.0 1 0.0
Unknown 3 0.2 1 0.1 4 0.1
**p <0.01; ***p <0.001.
†The column percentages were calculated using the total number of patients exposed
to LDPs (n=1649), TLDs (n=1150) and total (n=2799), respectively. Percentages might
not add up to 100% because some patients received more than one treatment.
LDP, laundry detergent pod; TLD, traditional laundry detergent.
Table 2 Clinical effects associated with laundry detergents among
children aged <5 years exposed in Italy between September 2010
and June 2015
LDPs TLDs Total
Clinical effects n %† n %† n %†
Association between exposure and clinical effects***
None/not associated 393 23.8 882 76.7 1275 45.6
Insufficient data 23 1.4 18 1.6 41 1.5
Associated 1233 74.8 250 21.7 1483 53.0
Severity of clinical effects***
Low 1076 87.3 249 99.6 1325 89.3
Moderate 147 11.9 1 0.4 148 10.0
High 10 0.8 0 0.0 10 0.7
Main clinical effects
Gastrointestinal** 937 76.0 166 66.4 1103 74.4
Vomiting 897 72.7 154 61.6 1051 70.9
Diarrhoea 129 10.5 8 3.2 137 9.2
Abdominal pain 26 2.1 4 1.6 30 2.0
Nausea 23 1.9 8 3.2 31 2.1
Heartburn 8 0.6 2 0.8 10 0.7
Oropharyngeal*** 330 26.8 31 12.4 361 24.3
Hyperaemia oral cavity 170 13.8 9 3.6 179 12.1
Irritation/pharyngeal pain 140 11.4 14 5.6 154 10.4
Drooling 108 8.8 5 2.0 113 7.6
Lips hyperaemia 7 0.6 4 1.6 11 0.7
Lips/oral cavity oedema 7 0.6 0 0.0 7 0.5
Lips/oral cavity de-epithelisation 7 0.6 0 0.0 7 0.5
Respiratory** 228 18.5 28 11.2 256 17.3
Cough 208 16.9 25 10.0 233 15.7
Dyspnoea 20 1.6 4 1.6 24 1.6
Laryngospasm/bronchospasm 19 1.5 0 0.0 19 1.3
Stridor 7 0.6 0 0.0 7 0.5
Wet rales 14 1.1 0 0.0 14 0.9
Bronchial hypersecretion 11 0.9 0 0.0 11 0.7
Respiratory failure 6 0.5 0 0.0 6 0.4
Glottis/oesophagus caustic
injuries/erosion
5 0.4 0 0.0 5 0.3
Glottis/epiglottis oedema 3 0.2 0 0.0 3 0.2
Chemical pneumonia 3 0.2 0 0.0 3 0.2
Ocular 209 17.0 44 17.6 253 17.1
Hyperaemia 198 16.1 39 15.6 237 16.0
Irritation/pain 184 14.9 34 13.6 218 14.7
Lachrymation 35 2.8 3 1.2 38 2.6
Photophobia 24 1.9 2 0.8 26 1.8
Corneal abrasion 22 1.8 0 0.0 22 1.5
Ptosis 19 1.5 1 0.4 20 1.3
Dermal 76 6.2 10 4.0 86 5.8
Hyperaemia 36 2.9 4 1.6 40 2.7
Oedema 20 1.6 1 0.4 21 1.4
Rash 8 0.6 0 0.0 8 0.5
Macule 5 0.4 1 0.4 6 0.4
**p<0.01; ***p<0.001.
†The column percentages referring to the ‘association between exposure and clinical
effects’ were calculated using the total number of patients exposed to LDPs
(n=1649), TLDs (n=1150) and total (n=2799), respectively; the column percentages
referring to ‘severity of clinical effects’ and the ‘main clinical effects’ were calculated
using the total number of patients with associated clinical effects exposed to LDPs
(n=1233), TLDs (n=250) and total (n=1483), respectively. The percentages referring
to ‘main clinical effects’ may not add up to 100% because some patients had more
than one clinical effect.
LDP, laundry detergent pod; TLD, traditional laundry detergent.
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OCs-LDPs (OR=11.3; 95% CI 8.8 to 14.7) in comparison with
TLDs. The analysis focusing only on patients exposed to LDPs
(table 4, model 2) showed that those exposed to MC-LDPs were
more likely (OR=1.8; 95% CI 1.2 to 2.7) to develop moderate/
high severity clinical effects in comparison with OCs-LDPs.
Furthermore, the odds of having moderate/high severity effects
was four times higher for children aged <1 year than for those
aged 3–4 years (reference group) (OR=3.9; 95% CI 2.2 to 7.0).
DISCUSSION
The results of this study corroborate findings from previous
investigations showing that paediatric exposure to LDPs are
more hazardous than those to TLDs.2–31
The main characteristics of paediatric patients exposed to
LDPs and TLDs in Italy were similar to those reported in a pre-
vious study based on data from the US National Poison Data
System.30 In particular, both studies show that among patients
exposed to LDPs the percentages of those aged 3 and 4 years,
exposed via multiple routes, managed at a hospital and with
clinical effects are higher than those reported for TLDs.
In both countries children exposed to LDPs have higher odds
of experiencing one or more clinical effect than those exposed
to TLDs. The OR based on the Italian data (OR=10.8; 95% CI
9.0 to 12.9) was more than twice that reported in the US study
(OR=3.9; 95% CI 3.7 to 4.1). This observation might be
explained by several factors, including differences in the popula-
tion served,33 36 pod users’ behaviour and products on the
market. The Italian study also highlighted a higher odds of
having high severity effects for patients exposed to MC-LDPs
than for those exposed to OCs-LDPs. This observation deserves
particular attention since it might be related to differences in
soluble packaging and/or intrinsic toxicity of mixtures.
During the study the number of patients exposed to TLDs
was stable (0.65 cases/day), whereas a sharp, statistically signifi-
cant decrease of exposure to MC-LDPs was seen in December
2012. The estimated values were reduced from 1.03 cases/day
and 1.88 cases/million units sold (observed between September
2010 and November 2012) to 0.36 cases/day (observed between
December 2012 and June 2015), and 0.86 cases/million units
(observed between December 2012 and December 2014). In
December 2012 a statistically significant reduction of the
Figure 1 Trends of monthly mean
number of cases/day exposed to major
company (MC)-laundry detergent pods
(LDPs) versus traditional laundry
detergents (TLDs) (A); other companies
(OCs)-LDPs versus TLDs (B) and trends of
number of cases/million caps sold
exposed to MC-LDPs and OCs-LDPs (C).
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number of patients exposed daily to OCs-LDPs was also
detected, reducing from 0.53 cases/day (observed between April
and November 2012) to 0.38 cases/day (observed between
December 2012 and September 2013). A further statistically sig-
nificant reduction occurred in October 2013, when the esti-
mated daily number of cases was reduced to 0.25 cases/day.
The initial changes seen in December 2012 occurred
4 months after the introduction of opaque outer packaging by
the MC for the majority of LDPs marketed in Italy. This action
might have been taken by some of the OCs at the same time
since a decrease of the number of patients exposed to OCs/day
was also detected. Previous preventive measures, including
an information campaign for safe use of LDCs, launched
between May and June 2012, and improvement of the outer
packaging lid to make it more difficult for children to open,
started in January 2012, were not followed by any detectable
effect on exposure frequency. The second change, specifically
with reference exposure to OCs-LDPs, occurred in Italy
5 months after it became compulsory to produce the new
products in opaque outer-packaging with a closure impeding the
ability of young children to open it.32 The available observations
suggest that reducing the visibility of MC-LDPs effectively
prevents young children from exposures, whereas other
preventive measures seem to be poorly effective if the product is
easily visible.
Exposures to LDCs are more frequently associated with mod-
erate/high severity clinical effects than exposure to TLDs, and
their attractiveness to children and intrinsic toxicity remains a
major concern for prevention of hazardous exposures and
injuries.
Like studies based on data from PCCs, our investigation has a
number of limitations. First, it relies on cases voluntarily submit-
ted to NPCCMi, representing an unknown proportion of those
actually occurring in the served population. Information is
mainly collected during the telephone call while the PCC spe-
cialist is providing diagnosis and treatment recommendations;
this implies that systematic differences may occur in data collec-
tion for cases of higher severity owing to the stress of manage-
ment. Nevertheless, PCCs are the most informative source for
poisoning and can raise an alert and guarantee surveillance of
specific exposures.
About 5% of cases initially extracted from the NPCCMi data-
base were excluded from the study because the type of laundry
detergent patients were exposed to was unknown. Among these
cases, 77% were asymptomatic and the remaining 23% reported
low severity outcomes. Distributions by age and site of manage-
ment were similar to those observed for TLDs, suggesting that
most of these patients were exposed to this type of detergent.
Two years after the introduction in Italy of obscured outer
packaging for LDCs, the same measure was made compulsory in
Europe,37 together with other requirements for soluble pack-
aging, including addition of an aversive agent to discourage chil-
dren from consuming the product, ensuring the pods retained
their liquid content for at least 30 s when placed in water at 20°
C and resisted a certain degree of standard mechanical
compression.
Surveillance of LDP-related cases identified by national PCCs
are needed to evaluate the effect of the new measures recently
made compulsory in Europe and adopted voluntarily in the
USA.30
Table 4 Logistic regression models for clinical effects (model 1) and their severity (model 2) after exposure to laundry detergents
Model 1
Including all patients exposed to laundry detergents
Cases
(n)
At least one
clinical effect
(%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Age (years)
<1 147 61.9 1.2 (0.8 to 1.7) 1.4 (0.9 to 2.2)
1–2 2009 50.7 0.7 (0.6 to 0.9) 1.0 (0.8 to 1.3)
3–4 643 58.2 1.0 1.0
Laundry detergent
TLDs 1150 21.7 1.0 1.0
MC-LDPs 1188 74.3 10.4 (8.6 to 12.6) 10.5 (8.6 to 12.8)
OCs-LDPs 461 75.9 11.4 (8.8 to 14.7) 11.3 (8.8 to 14.7)
Exposure period
September 2010–November 2012 1593 55.7 1.0 1.0
December 2012–June 2015 1206 49.3 0.8 (0.7 to 0.9) 1.0 (0.9 to 1.3)
Model 2
Including patients exposed to LDPs
Cases
(n)
Moderate/high severity
outcomes (%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Age (years)
<1 95 25.3 3.9 (2.2 to 6.9) 3.9 (2.2 to 7.0)
1–2 1105 8.8 1.1 (0.7 to 1.6) 1.1 (0.8 to 1.7)
3–4 449 8.0 1.0 1.0
Laundry detergent
OCs-LDPs 461 6.9 1.0 1.0
MC-LDPs 1188 10.5 1.6 (1.1 to 2.4) 1.8 (1.2 to 2.7)
Exposure period
September 2010–November 2012 1033 8.7 1.0 1.0
December 2012–June 2015 616 10.9 1.3 (0.9 to 1.8) 1.5 (1.0 to 2.1)
LDP, laundry detergent pod; MC, major company; OCs, other companies; TLD, traditional laundry detergent.
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What is already known on the subject
▸ Previous investigations have shown that laundry detergents
in pods have the potential to cause corrosive eye damage,
pulmonary toxicity and serious laryngopharyngeal injuries in
young children.
▸ Prevention of hazardous exposures to these products
remains a major concern.
What this study adds
▸ Making these products less visible through the adoption of
opaque outer packaging is likely to reduce the occurrence of
exposure to pods.
▸ Further efforts are needed to reduce attractiveness to
children of laundry detergents in pods and reduce their
ability to cause injuries and poisoning following exposure.
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